ERBB2 and cancer: Similarly, the HLA-G-blocking antibody remarkably enhanced the ADCC activity of NK cells with respect to HER2-positive cancer cells, but not those that negligibly expressed HER2 (Fig. 1g and Supplementary Fig. S1).